With one change made by one pharmaceutical company, we could save half a million trees every year. Imagine the impact if the change was made across industry.
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.